3SBio   Report issue

For profit Phase 1 Phase 2 Phase 3
Founded: Shenyang China (1993)
Status: Acquired by Shanghai CP Guojian Pharmaceutical Co.,Ltd. (2015)

Organization Overview

First Clinical Trial
2018
NCT03657238
First Marketed Drug
None
First NDA Approval
None
Last Known Activity
2020

Timeline

NOW
  • Now

Mergers & Acquisitions

Historical Acquisition Tree

Alternative names

Shengzhen Sciprogen Bio-pharmaceutical Co. Ltd

Active Ingredients

Drugs in Phase 3 Trials (1)

Key: 3SBio (0) Acquired (1)

immune globulin (human) (Gamastan) (1 trial)

Drugs in Phase 2 Trials (1)

epoetin (Epogen) (2 trials)

Drugs in Phase 1 Trials (1)

Key: 3SBio (0) Acquired (1)

tbi 302 (1 trial)

Indications

Experimental Indications (Clinical Trials, Phases 1-4)


 

Anemia (Phase 2)

Kidney Failure, Chronic (Phase 2)

Renal Insufficiency (Phase 2)

Renal Insufficiency, Chronic (Phase 2)

Overview

  • Highest Phase: Phase 2
  • # of Trials: 4
  • # of Trial APIs: 3